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outcomes, 1 duplicate publication, 3 review articles, and 4 articles that did not
differentiate nocturia from other urinary symptoms. A total of 14 studies were
included in the analysis. Six major constructs of sleep were used. Five validated
measurement tools were utilized by eight different studies. Nocturia was associ-
ated with an increase in sleep disturbance, increase in napping, increase in insom-
nia risk, and overall decrease of sleep quality, but the lack of a consistent outcome
measures prevented quantitative synthesis.CONCLUSIONS:Nocturia is associated
with an increase risk of falls and fractures. It is also associated with a decrease in
sleep quality and increase in sleep disturbance.
URINARY/KIDNEY DISORDERS – Cost Studies
PUK9
ESTIMATION OF PREVALENCE AND ECONOMIC BURDEN OF ACUTE KIDNEY
INJURY FROM A MANAGED CARE DATABASE IN THE UNITED STATES
Hopkins B1, Obi-tabot E1, Wang H1, Wang Y1, Blount T2, Muszka J1
1Sanofi-Aventis, Bridgewater, NJ, USA, 2Sanofi-Aventis, Bridegwater, NJ, USA
OBJECTIVES: Widely disparate definitions of renal injury or failure have histori-
cally been used in epidemiologic studies, not always in accordance with the RIFLE
(risk, injury and failure) criteria. This has resulted in awide range of incidence rates
in the published literature. The clinical epidemiology analysis of AKI estimates an
incidence rate of 200/100,000 in the all-age population and 25/100,000 in the all-age
population receiving renal replacement therapy. Our objective was to estimate the
prevalence and examine the related health care burden of acute kidney injury
(AKI). METHODS: Patients diagnosed with AKI in 2009 were identified in the Op-
tumInsight Impact database. Projections for the US Population were based on the
age-adjusted prevalence per 100,000 for patients with at least one paid claim that
specified an AKI diagnosis during 2009. A sample matched for age and gender was
created to compare health care costs. RESULTS: Based on the age-adjusted preva-
lence in the OptumInsight Impact database of 480 per 100,000 patients in 2009, the
projection to the US population was 1,473,232 individuals with AKI; 40% of these
patients were exposed to contrast media; nearly 30% had cardiovascular (CV) sur-
gery, and over 20% of patients also hadmajor digestive surgery. Mean annual costs
in 2009 were $64,594, including outpatient, inpatient, ER, and pharmacy
(N116,994 AKI patients). This included costs specifically related to AKI ($19,115).
Among AKI patients that had dialysis, the mean annual procedure-related costs
($44,065, N10,879) were comparable to all patients receiving dialysis ($46,884).
However, AKI patients typically demonstrated substantially higher procedure-re-
lated costs for major digestive surgery, major CV surgery, and contrast media ex-
posure, in comparison to all patients undergoing each of these procedures.
CONCLUSIONS: AKI prevalence was higher than expected, and was associated
with a high economic burden as demonstrated by procedure-related costs. To un-
derstand the pattern of risk, longitudinal examination is needed.
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OBJECTIVES: The increasing number of patients developing end-stage renal dis-
ease (ESRD) is driving up the costs of care dramatically. Effective January 1, 2011,
Medicare implemented a bundled prospective payment system (PPS). This study
investigates the five-year budget impact on Medicare under the new PPS of chang-
ing the distribution of patients undergoing peritoneal dialysis (PD) and in-center
hemodialysis (ICHD). METHODS: We constructed an Excel®-based budget impact
model to assess dialysis-associatedMedicare costswhen shifting patients between
PD and ICHD. The model incorporates the current modality distribution and ac-
counts for Medicare dialysis payments (including start-up costs), oral drug costs,
and the costs and probabilities of adverse events including access failure, access
infection, pneumonia, and cardiovascular events. Data from the United States Re-
nal Data System (USRDS) were used to estimate the US Medicare dialysis patient
population for the next five years. The baseline scenario assumed a stable distri-
bution of PD (8.0%) and ICHD (90.5%) over five years; the remaining 1.5% is assumed
to practice home hemodialysis. Alternative scenarios assumed the prevalence of
PD decreased by 0.5% or increased by 0.5% or 1% each year for five years, with
commensurate changes in ICHD. Differences among scenarios were evaluated in
terms of costs to Medicare and numbers of adverse events. RESULTS: Under the
bundled PPS, an increase in the prevalent PD population from 8.0% in 2012 to 10%
or 12% in 2016 is predicted to result in five-year cumulative savings for Medicare of
$37 million and $74 million, respectively. If the prevalent PD population were to
decrease from 8.0% in 2012 to 6.0% by 2016, the total Medicare payment for dialysis
patients would increase by $37 million over 5 years CONCLUSIONS: Under Medi-
care bundled PPS, shifting patients from ICHD to PD could help Medicare reduce
dialysis-associated costs.
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OBJECTIVES: To compare retrospective data of erythropoiesis-stimulating agent
(ESA) dosing patterns and costs among hospital outpatients with dialysis chronic
kidney disease (CKD) not on dialysis. METHODS: Electronic records from the Pre-
mier hospital database (2006Q1-2011Q1) were used to identify outpatients that had
a diagnosis for CKD and received epoetin alfa (EPO) or darbepoetin alfa (DARB).
Exclusion criteria were: age 18 years, receipt of renal dialysis, a diagnosis of
cancer or myelodysplastic syndrome, receipt of chemotherapy, or receipt of both
ESAs. The observation period consisted of the outpatient continuous ESA episode,
defined as the period from first to last outpatient visit with ESA use without a gap
of more than one calendar month between ESA visits. The ESA dose ratio (Units
EPO: mcg DARB) was calculated using themean cumulative dose of EPO and DARB.
Treatment costs for both ESA groups were determined using cumulative dose and
published July 2011 wholesale acquisition costs. RESULTS: A total of 9770 outpa-
tient ESA episodes (EPO: 5398; DARB: 4,72) were identified. EPO and DARB groups
had a similar mean age (73.1 vs. 73.5 years, respectively; P0.104) and similar
proportion of females (59.4% vs. 59.0%, respectively; P0.663). EPO group had a
longer duration of outpatient episode (3.8months vs. 3.4months, P0.001) than the
DARB group. Themean cumulative dose was EPO 174,010 Units and DARB 622mcg,
which resulted in a dose ratio (Units EPO:mcg DARB) of 280:1. Correspondingmean
ESA treatment costs were higher for DARB than for EPO (EPO: $2,819 vs. DARB:
$3,484, P0.001). CONCLUSIONS: In this analysis of non-dialysis CKD hospital out-
patient records, a dose ratio (Units EPO: mcg DARB) of 280:1 was observed. Mean
ESA treatment costs were found to be approximately 24% higher for the DARB
group as compared to the EPO group.
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OBJECTIVES: To compare retrospective data of erythropoiesis-stimulating agent
(ESA) dosing patterns and costs among hospital inpatients with chronic kidney
disease (CKD) not on dialysis.METHODS: Electronic records from the Premier Hos-
pital Database (2006Q1-2011Q1) were used to identify inpatients that had a diag-
nosis for CKD and had received epoetin alfa (EPO) or darbepoetin alfa (DARB).
Exclusion criteria were:18 years, receipt of renal dialysis, a diagnosis of cancer or
myelodysplastic syndrome, receipt of chemotherapy, or receipt of both ESAs. The
observation period consisted of the hospital inpatient stay. The dose only ratio
(Units EPO: mcg DARB) was calculated using the mean cumulative dose of EPO and
DARB. Treatment costs for both ESA groups were determined using cumulative
dose and published July 2011 wholesale acquisition costs. RESULTS: A total of
135,432 inpatient stays (EPO: 104,195; DARB: 31,237) were identified. The EPO group
was slightly younger than the DARB group (69.5 vs. 70.0 years, respectively;
P0.001), and had a higher proportion of females (52.1% vs. 51.2%, respectively;
P0.022). Length of stay (LOS) was similar withmean LOS of EPO9.3 vs. DARB9.2
days, (P0.084). The mean cumulative dose was EPO 35,355 Units and DARB 128
mcg, which resulted in a dose only ratio (Units EPO: mcg DARB) of 276:1. Corre-
sponding mean ESA treatment costs were higher for DARB than for EPO (EPO: $573
vs. DARB: $718; P0.001). CONCLUSIONS: In this analysis of non-dialysis CKD in-
patient records, a dose only ratio (Units EPO: mcg DARB) of 276:1 was observed.
Mean ESA treatment costswere found to be approximately 25%higher for theDARB
group versus EPO group despite similar length of stay between the groups.
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OBJECTIVES: To understand the trends in rate and cost of hospitalizations due to
Chronic Kidney Disease (CKD) in the United States. METHODS: We analyzed last
five years of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage
Renal Disease (ESRD). The annual number of hospitalizations for specific diagnosis
were obtained from AHRQ’s National In-patient Sample (NIS) databases of 2005-
2009. Data were also analyzed for length of stay (LOS), charges and cost of
hospitalization. RESULTS: During last five years the number of hospitalizations
with diagnosis of CKD and ESRD have increased 4.1 and 4.6 fold, respectively. In
2009, an estimated 1,634,422 and 931,641 hospitalizations were with diagnosis of
CKD and ESRD, respectively. The mean LOS for patients with CKD has increased
from 4.9 to 5.5 days, during 2005-2009. The mean LOS for patients with ESRD has
remained steady at 6 days during 2005-2009. The cost of hospitalization with
diagnosis of CKD has increased 31% during 2005-2009. The cost of hospitalization
with diagnosis of ESRD has increased 21% during 2005-2009. In 2009, themean cost
of hospitalization for patients with CKD and ESRD were $11,209 and $21,358,
respectively. CONCLUSIONS: Hospitalizations due to CKD and ESRD have signifi-
cantly increased during last five years. There is a need for prevention, treatment
and disease management programs to lower the medical and socioeconomic bur-
den of this disease.
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